Related Experiment Videos
Establishment and characterization of a new, factor-independent acute myeloid leukemia line designated Ei501
E Weidmann1, J Brieger, T Karakas
1Medical Clinic III, Department of Internal Medicine, University Hospital, Johann-Wolfgang Goethe University, Frankfurt/M, Germany.
Abstract:
We established a factor-independent acute myeloid leukemia cell line, designated Ei501. The line has been growing in RPMI 1640 media for 18 months and can be maintained without addition of growth factors. Ei501 is positive for myeloperoxidase and negative for esterase and PAS. Cytogenetic analysis revealed the FAB M3 associated t(15;17) translocation and a translocation of the chromosomes 7 and 8: 46 XX, -7, +t(7;8)(q32;q13), t(15;17)(q22;q12). This karyotype was confirmed by fluorescence in situ hybridization. Ei501 cells express AML-associated surface markers such as CD13, CD33 and CD38. Although 42% of the patient's blast cells were CD34-positive, the line lacks surface expression of CD34. Furthermore the line has a number of characteristics which are detectable in blasts from AML patients, such as surface adhesion molecules, cytokines such as TGF-beta, cytokine receptors such as the IL-2 receptor beta and gamma chains or the IL-4 receptor and the genes for the transcription factor wt-1 (Wilms' tumor gene) and for the proto-oncogene bcl-2, both shown to be present in the majority of patients with AML. Additionally the line can be used as target in cytotoxicity assays using IL-2 activated cytotoxic lymphocytes as effector cells. In conclusion, besides a rare karyotype the Ei501 cell line has several features common in AML, and may therefore be used as a model to study pathogenetic mechanisms in acute myeloid leukemia.
Insights
A new acute myeloid leukemia (AML) cell line, Ei501, was developed. This factor-independent line exhibits common AML features and a rare karyotype, making it a valuable model for studying AML pathogenesis.
Area of Science:
- Hematology
- Cell Biology
- Cancer Research
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Development of reliable cell line models is crucial for understanding AML pathogenesis and for therapeutic target identification.
Observation:
- A novel factor-independent AML cell line, Ei501, was established and characterized.
- Ei501 cells are myeloperoxidase-positive and express AML-associated surface markers (CD13, CD33, CD38), but lack CD34 expression.
- Cytogenetic analysis revealed a unique karyotype: 46 XX, -7, +t(7;8)(q32;q13), t(15;17)(q22;q12), confirmed by FISH.
Findings:
- The Ei501 cell line exhibits several characteristics found in primary AML blasts, including surface adhesion molecules, expression of TGF-beta, IL-2 receptor (beta and gamma chains), IL-4 receptor, and the genes for wt-1 and bcl-2.
- The cell line can be maintained without growth factors, simplifying its use in research.
- Ei501 serves as a target in cytotoxicity assays with IL-2 activated cytotoxic lymphocytes.
Implications:
- The Ei501 cell line provides a unique model for investigating the molecular mechanisms underlying AML, particularly those associated with its specific karyotype.
- Its factor-independent growth and expression of key AML markers facilitate research into disease progression and potential therapeutic strategies.
- This cell line can aid in the development and testing of novel immunotherapies for AML.